Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Interest Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Interest Expenses for 12 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses rose 7.04% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.2 million, a 9.36% increase, with the full-year FY2024 number at $6.9 million, down 24.4% from a year prior.
  • Interest Expenses was $1.8 million for Q3 2025 at Marimed, up from $1.8 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.6 million in Q2 2023 to a low of $200000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.6 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: crashed 92.57% in 2021, then skyrocketed 700.32% in 2023.
  • Marimed's Interest Expenses stood at $279413.0 in 2021, then skyrocketed by 51.03% to $422000.0 in 2022, then surged by 269.19% to $1.6 million in 2023, then grew by 21.05% to $1.9 million in 2024, then decreased by 3.23% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Interest Expenses are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $1.8 million (Q1 2025).